project . 2015 - 2018 . Closed

HemAcure

Application of combined gene and cell therapy within an implantable therapeutic device for the treatment of severe hemophilia A
Open Access mandate for Publications European Commission
  • Funder: European CommissionProject code: 667421 Call for proposal: H2020-PHC-2015-two-stage
  • Funded under: H2020 | RIA Overall Budget: 5,564,400 EURFunder Contribution: 5,564,400 EUR
  • Status: Closed
  • Start Date
    01 Nov 2015
    End Date
    31 Oct 2018
  • Detailed project information (CORDIS)
  • Open Access mandate
    Research Data: No
Description
The main objective of the HemAcure project is to develop and refine the tools and technologies for a novel ex vivo prepared cell based therapy to treat the bleeding disease haemophilia A (caused by genetic deficiency in clotting factor VIII (FVIII)) that should ultimately lead to improved quality of life of the patients. The concept is a further development of our approach, established during the FP7 ReLiver project led by Medicyte. From the very beginning, we balance two important goals, maximizing the product’s efficacy and safety profile on one side and minimizing production cost on the other by enhancing the product’s manufacturability. HemAcure relates to t...
Description
The main objective of the HemAcure project is to develop and refine the tools and technologies for a novel ex vivo prepared cell based therapy to treat the bleeding disease haemophilia A (caused by genetic deficiency in clotting factor VIII (FVIII)) that should ultimately lead to improved quality of life of the patients. The concept is a further development of our approach, established during the FP7 ReLiver project led by Medicyte. From the very beginning, we balance two important goals, maximizing the product’s efficacy and safety profile on one side and minimizing production cost on the other by enhancing the product’s manufacturability. HemAcure relates to t...
Any information missing or wrong?Report an Issue